This article refers to 'Effects of dapagliflozin in heart failure with reduced ejection fraction, and chronic obstructive pulmonary disease: an analysis of DAPA-HF' by P. Dewan et al., published in this issue on pages 632-643.
Chronic obstructive pulmonary disease and comorbidities in heart failure: the next frontier of sodium–glucose co-transporter 2 inhibitors?
Canepa M.;Ameri P.;
2021-01-01
Abstract
This article refers to 'Effects of dapagliflozin in heart failure with reduced ejection fraction, and chronic obstructive pulmonary disease: an analysis of DAPA-HF' by P. Dewan et al., published in this issue on pages 632-643.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Canepa - EJHF 2021 EDIT COPD and SGLT2i editorial.pdf
accesso chiuso
Tipologia:
Documento in versione editoriale
Dimensione
549.8 kB
Formato
Adobe PDF
|
549.8 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
